


FL118

Cat. No.:	HY-12486		
CAS No.:	135415-73-5		
Molecular Formula:	C ₂₁ H ₁₆ N ₂ O ₆		
Molecular Weight:	392.36		
Target:	Survivin; Apoptosis; IAP		
Pathway:	Apoptosis		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 1 mg/mL (2.55 mM; ultrasonic and warming and heat to 60°C)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.5487 mL	12.7434 mL	25.4868 mL
5 mM	---	---	---
10 mM	---	---	---

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

FL118 (10,11-(Methylenedioxy)-20(S)-camptothecin), a [Camptothecin](#) (HY-16560) analogue, is a potent and orally active survivin inhibitor. FL118 binds to oncoprotein DDX5 (p68) to dephosphorylates and degrades DDX5. FL118 can be used for the research of cancer^{[1][2]}.

In Vitro

FL118 (0-200 nM; 24, 48 and 72 h) inhibits the cell proliferation of ES-2 and SK-O-V₃ cells^[1].
 FL118 (0-100 nM; 0 and 24 h) inhibits the migration of ES-2 and SK-O-V₃ cells^[1].
 FL118 (0-100 nM; 48 h) affects the expression level of cytoglobin (CYGB)^[1].
 FL118 (10 and 100 nM; 48 h) inhibits PI3K/AKT/mTOR signaling pathway, and affects the expression level of vimentin and E-cadherin in ovarian cancer cells^[1].
 FL118 (0-100 nM; 6 and 24 h) dephosphorylates and degrades DDX5^[2].
 FL118 (0-500 nM; 24, 48, 72 h) regulates survivin, Mcl-1, XIAP, cIAP2, c-Myc and mKras by regulating DDX5^[2].
 FL118 (0-1 μM, 24 h) shows significant cytotoxic activity against the three tumor cell lines (A549, MDA-MB-231, and RM-1 cells)^[3].
 FL118 (0-10 nM, 48 h) increases the production of PARP cleavage, and induces apoptosis in A549^[3].
 FL118 (0-10 nM, 48 h) arrests A549 cells mainly at the G2/M phase^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:	ES-2 and SK-O-V ₃ cell lines
Concentration:	10 and 100 nM
Incubation Time:	48 h
Result:	Effectively inhibited the activation of PI3K/AKT/mTOR signaling pathway in ovarian cancer cells and also inhibited the migration of ES-2 and SK-O-V ₃ cells.

Cell Migration Assay ^[1]

Cell Line:	ES-2 and SK-O-V ₃ cell lines
Concentration:	0, 10 and 100 nM
Incubation Time:	0 and 24 h
Result:	Inhibited the migration of ES-2 and SK-O-V ₃ cells dose-dependently.

RT-PCR^[1]

Cell Line:	ES-2 and SK-O-V ₃ cell lines
Concentration:	0, 10 and 100 nM
Incubation Time:	48 h
Result:	Promoted CYGB expression.

Cell Proliferation Assay^[1]

Cell Line:	ES-2 and SK-O-V ₃ cell lines
Concentration:	0, 1, 10, 50, 100 and 200 nM
Incubation Time:	24, 48 and 72 h
Result:	Inhibited the cell proliferation of ES-2 and SK-O-V ₃ cells time- and dose-dependently.

Western Blot Analysis^[2]

Cell Line:	SW620 and Mia Paca-2
Concentration:	0, 10 and 100 nM
Incubation Time:	6 and 24 h
Result:	Induced dephosphorylation of DDX5 through the ubiquitin-proteasome degradation pathway and degraded DDX5 time-dependently.

Western Blot Analysis^[2]

Cell Line:	PDAC Panc1, CRC HCT-8, SW620, Mia Paca-2, Panc-1, HCT-8 cell lines
Concentration:	0, 10, 100 and 500 nM
Incubation Time:	24, 48, 72 h

Result:	Controlled the expression of survivin, Mcl-1, XIAP, cIAP2, c-Myc and mKras by regulated DDX5, as an upstream master regulator in cancer development and malignant networks.
---------	---

Cell Cytotoxicity Assay^[3]

Cell Line:	A549, MDA-MB-231, RM-1
Concentration:	0-1 μ M
Incubation Time:	24 h
Result:	Showed cytotoxicity in A-549 (human lung carcinoma), MDA-MB-231 (human breast carcinoma) and RM-1 (mouse prostate carcinoma), with IC ₅₀ values of 8.94 \pm 1.54 , 24.73 \pm 13.82, and 69.19 \pm 8.34 nM, respectively.

Apoptosis Analysis^[3]

Cell Line:	A549 cells
Concentration:	0, 2.5, 5, 10 nM
Incubation Time:	48 h
Result:	Resulted in the downregulation of survivin. Increased the production of PARP cleavage in a concentration-dependent manner, which is the hallmark of apoptosis. Induced apoptosis in A549.

Cell Cycle Analysis^[3]

Cell Line:	A549 cells
Concentration:	0, 2.5, 5, 10 nM
Incubation Time:	48 h
Result:	Increased G2/M cell population in a concentration-dependent manner, and arrested A549 cells mainly at the G2/M phase.

In Vivo

FL118 (5 and 10 mg/kg; p.o. once a week for 20 days) inhibits antitumor activity^[1].
 FL118 (0-1.5 mg/kg, i.p. once every other day for five times) effectively eliminates human colon and head-and-neck tumors that acquire irinotecan or topotecan resistance^[4].
 FL118 (1.5 mg/kg, i.v. once) exhibits favorable pharmacokinetics profiles^[4].
 Pharmacokinetic Parameters of FL118 in female SCID mice^[4].

Sample	FaDu	SW620	Plasma
T _{1/2} (hr)	6.852	12.75	1.788
T _{max} (hr)	0.167	0.167	0.167
C _{max} (ng/g, mL)	115	158	43
AUC (hr*ng/g)	413	842	82

AUC _∞ (hr*ng/g)	448	897	104
AUC% Extrap (%)	7.74	6.17	21.7
Vz (g/kg) (ml/kg)	33052	30742	36849
Cl (g/hr/kg) (ml/hr/kg)	3343	1671	14287

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female BALB/c nude mice ^[1]
Dosage:	5 and 10 mg/kg
Administration:	Oral gavage; 5 mg/kg for once a week; 10 mg/kg for once a week; for 20 days
Result:	Showed better antitumor activity than topotecan and dose-dependently suppressed the growth of ES-2 tumors by upregulating the expression level of CYGB.

Animal Model:	SCID (severe combined immunodeficiency) mice bearing human SW620 (colon) and FaDu (head-and-neck) xenograft tumors (ten-week-old, female, 20-25 g, 5 mice per cage) ^[4]
Dosage:	0, 0.75, 1, 1.5 mg/kg
Administration:	IP, once every other day for five times as one cycle (If tumors relapse, mice were treated with FL118 for second or third cycles)
Result:	Eliminated human xenograft tumors that acquired irinotecan or topotecan resistance, and was also effective after multiple cycles of treatment without the generation of FL118 resistance.

Animal Model:	SCID (severe combined immunodeficiency) mice bearing human SW620 (colon) and FaDu SCID mice bearing human SW620 (colon) and FaDu (head-and-neck) xenograft tumors (ten-week-old, female, 20-25 g, 5 mice per cage) ^[4]
Dosage:	1.5 mg/kg
Administration:	IV, once
Result:	Exhibited favorable pharmacokinetics profiles.

REFERENCES

[1]. Zhao H, et al. FL118, a novel anticancer compound, inhibits proliferation and migration of ovarian cancer cells via up-regulation of cytoglobin in vivo and in vitro[J]. Translational Cancer Research, 2017, 6(6):1294-1304.

[2]. Ling X, et al. FL118, acting as a 'molecular glue degrader', binds to dephosphorylates and degrades the oncoprotein DDX5 (p68) to control c-Myc, survivin and mutant Kras against colorectal and pancreatic cancer with high efficacy. Clin Transl Med. 2022 May;12(5):e881.

[3]. Wu G, et al. Synthesis of novel 10,11-methylenedioxy-camptothecin glycoside derivatives and investigation of their anti-tumor effects in vivo. RSC Adv. 2019 Apr 9;9(20):11142-11150.

[4]. Ling X, et, al. FL118, a novel camptothecin analogue, overcomes irinotecan and topotecan resistance in human tumor xenograft models. Am J Transl Res. 2015 Oct 15;7(10):1765-81.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA